Lung CancerNNALNCT00863824
Clearance of NNAL and Cotinine From Second-hand Smoke in Hair and Urine
An observational study of Lung Cancer, run by University of Nebraska.
Trial summary
This study will investigate how long it takes for NNAL and cotinine, markers of second hand smoke, to clear the human body. Read more about this study
- Who is it for?
- Ages 19 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Lung Cancer
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- Jul 2009to 11 May 2010
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Healthy Caucasians and African Americans who are ready to quit smoking.
Who may be able to join
- Healthy Caucasians and African-Americans 19 years of age or above, how are ready to quit smoking
Who cannot join
- Anyone who is not a Caucasian or an African-American, below 19 years of age, and is currently taken prescription medication.
About this study
Official title: Elimination of NNAL and Cotinine From Hair and Urine
This study will investigate how long it takes for NNAL and cotinine, markers of second hand smoke, to clear the human body.
Read the detailed description
The purpose of the study is to investigate how long it takes for NNAL and cotinine, both specific markers of second hand tobacco smoke exposure to clear the human body.
- Conditions
- Lung Cancer
- Keywords
- NNAL, Cotinine, Second hand smoke
- Medical subject headings
- Lung Neoplasms
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Mar 2009 (estimated)
- Study startJul 2009 (estimated)
- Primary completion11 May 2010
- Study completion11 May 2010
Why it stopped: Study was not funded
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by University of NebraskaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Nebraska
- Sponsor type
- University, hospital or other
- Collaborators
- Centers for Disease Control and Prevention
- Responsible party
- Sponsor
- Investigators
- Chandran Achuatn, PhD, Principal investigator, University of Nebraska
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00863824
- Sponsor's protocol ID
- 0121-09-EP
- Acronym
- NNAL
- Status last verified
- Aug 2023
- First submitted
- 17 Mar 2009
- Last updated
- 14 Aug 2023
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Elimination of NNAL and Cotinine From Hair and Urine
- ClinicalTrials.gov ID
- NCT00863824
- Acronym / sponsor ID
- NNAL / 0121-09-EP
- Conditions
- Lung Cancer
- Keywords
- NNAL, Cotinine, Second hand smoke
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: Study was not funded
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University of NebraskaUniversity, hospital or other
- Collaborators
- Centers for Disease Control and Prevention
- Study start
- Jul 2009 (estimated)
- Primary completion
- 11 May 2010 (actual)
- Study completion
- 11 May 2010 (actual)
- First posted
- 18 Mar 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will investigate how long it takes for NNAL and cotinine, markers of second hand smoke, to clear the human body.
Detailed description
The purpose of the study is to investigate how long it takes for NNAL and cotinine, both specific markers of second hand tobacco smoke exposure to clear the human body.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 19 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Healthy Caucasians and African Americans who are ready to quit smoking.
Key inclusion criteria (1 listed)
- Healthy Caucasians and African-Americans 19 years of age or above, how are ready to quit smoking
Key exclusion criteria (1 listed)
- Anyone who is not a Caucasian or an African-American, below 19 years of age, and is currently taken prescription medication.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2023.
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chandran Achuatn, PhD principal investigator
University of Nebraska
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer, run by University of Nebraska.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 14 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2023.